Targeting the TIGIT/CD155 axis is appealing as TIGIT and CD155 were each found to be highly expressed by Tregs and MDSCs, respectively, where CD155s expression by stromal or epithelial cells in particular was associated with worse survival in HNSCC patients (Wu et al., 2019). This evidence concerns the gene PVR and head and neck squamous cell carcinoma.